Show simple item record

dc.contributor.authorGhotaslou, R
dc.contributor.authorLeylabadlo, HE
dc.contributor.authorAsl, YM
dc.date.accessioned2018-08-26T05:41:51Z
dc.date.available2018-08-26T05:41:51Z
dc.date.issued2015
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/40555
dc.description.abstractTo review previous studies (the last 6 years) about the Helicobacter pylori (H. pylori) antibiotic resistance in order to evaluate the trend in antibiotic resistance.In this study, the PubMed, MEDLINE, Science Direct, Google Scholar and Scielo manuscripts were reviewed from 2009 to 2014.On the whole rates of H. pylori antibiotic resistance were 47.22% (30.5%-75.02%) for metronidazole, 19.74% (5.46%-30.8%) for clarithromycin, 18.94% (14.19%-25.28%) for levofloxacin, and 14.67% (2%-40.87%) for amoxicillin, 11.70% (0%-50%) for tetracycline, 11.5% (0%-23%) for furazolidon and 6.75% (1%-12.45%) for rifabutin. The frequency of tetracycline, metronidazole and amoxicillin resistance was higher in Africa, while clarithromycin and levofloxacin resistance was higher in North America and Asian, respectively.The most sensitive drug is rifabutin and the lowest sensitive drug is metronidazole in the world. The worldwide H. pylori antibiotic resistance to clarithromycin and levofloxacin has increased during the last 6 years. The present systematic review show alarming results and a novel plan is needed for eradication therapy of H. pylori infections.
dc.language.isoEnglish
dc.relation.ispartofWorld journal of methodology
dc.titlePrevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.
dc.typearticle
dc.citation.volume5
dc.citation.issue3
dc.citation.spage164
dc.citation.epage74
dc.citation.indexPubmed
dc.identifier.DOIhttps://doi.org/10.5662/wjm.v5.i3.164


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record